Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCyte BiotechPMCB +0.18%34 3-Year Share Buyback Ratio is 13.90 as of Apr. 2026. GuruFocus rates PMCB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,189 Biotechnology companies, PharmaCyte Biotech ranks better than 99.5% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. PharmaCyte Biotech's current 3-Year Share Buyback Ratio was 13.90%.
The historical rank and industry rank for PharmaCyte Biotech's 3-Year Share Buyback Ratio or its related term are showing as below:
PMCB'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -197 Med: -21.3 Max: 31
Current: 13.9
During the past 13 years, PharmaCyte Biotech's highest 3-Year Share Buyback Ratio was 31.00%. The lowest was -197.00%. And the median was -21.30%.
PMCB's 3-Year Share Buyback Ratio is ranked better than 99.5% of 1189
companies
in the Biotechnology industry
Industry Median: -11.8
vs PMCB: 13.90
PharmaCyte Biotech (NAS:PMCB) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
PharmaCyte Biotech 3-Year Share Buyback Ratio Related Terms
PMCB vs NIKI, IMNN, AIM: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, PharmaCyte Biotech's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's 3-Year Share Buyback Ratio falls into.
PharmaCyte Biotech 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 13.90 mean?
PharmaCyte Biotech (PMCB) has a 3-Year Share Buyback Ratio of 13.90 as of Apr. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #6 out of 1189 companies in the Biotechnology industry, placing it in the top 0.5%.
Is PharmaCyte Biotech's 3-Year Share Buyback Ratio too high?
PharmaCyte Biotech's current 3-Year Share Buyback Ratio is 13.90. Based on the distribution chart, PharmaCyte Biotech ranks #6 out of 1189 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's 3-Year Share Buyback Ratio compare to NIKI and IMNN?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #6 out of 1189 companies for 3-Year Share Buyback Ratio. This places PharmaCyte Biotech in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current 3-Year Share Buyback Ratio is 13.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current 3-Year Share Buyback Ratio of 13.90. The current 3-Year Share Buyback Ratio is 13.90. PharmaCyte Biotech's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current 3-Year Share Buyback Ratio is 13.90 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
34GF Score
Get the complete analysis for PMCB
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
